Archives
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
A high throughput screening campaign led to the
2024-02-04

A high-throughput screening campaign led to the discovery of the first series of both potent and selective ATR kinase inhibitors by Vertex Pharmaceuticals (Charrier et al., 2011). One of these compounds, VE-821, was shown to be a potent ATP-competitive inhibitor of ATR with minimal cross-reactivity
-
Most of lipid lowering agents
2024-02-04

Most of lipid-lowering agents have many therapeutic problems with severe side effects, while dietary fibers as lipid lowering therapy are safer. Chitosan (CS) is a dietary fiber biodegradable, biocompatible and has many health benefits including wound healing, antiinflammatory, anti-cancers, immune-
-
The therapeutic potential of ML induced MET against cells of
2024-02-04

The therapeutic potential of ML327-induced MET against DL-AP5 Sodium salt synthesis of mesenchymal origin has not been explored. In the present study, we hypothesized that induction of MET using ML327 would block the growth of ES cells and sensitize to TRAIL-mediated apoptosis. Herein, we report th
-
Numerous epidemiological studies document fewer cardiovascul
2024-02-04

Numerous epidemiological studies document fewer cardiovascular events and increased survival of non-CKD individuals treated with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARBs) [8], [9]. By contrast, there are few studies of cardiovascular benefits of interruption
-
br Concluding remarks br Conflict of interest br Acknowledgm
2024-02-04

Concluding remarks Conflict of interest Acknowledgment This work was supported by the H.E.B. Endowed Chair in Marine Science (to P.T.) and University of Texas Marine Science Institute endowment-supported scholarships (to A.C). Introduction Disorders of sex development (DSD) are defined
-
Herein we disclose novel dihydropyrano
2024-02-02

Herein, we disclose novel 2,4-dihydropyrano[2,3-c]pyrazoles that inhibit human ATX (hATX). Our results demonstrate and further support previous findings showing that a desired biological action can be achieved without targeting the catalytic site of the enzyme. Moreover, this study validated hen egg
-
Various cardiovascular diseases show a high occurrence of
2024-02-02

Various cardiovascular diseases show a high occurrence of autophagosomes. Whereas basal autophagy is required for the proper functioning of cardiomyocytes [82], the deletion of Atg5 gene in myocardium shows a high risk of cardiomyopathy [83]. Hamacher et al. observed that an upregulation of Bnip3, a
-
There are profound differences between
2024-02-02

There are profound differences between acute and chronic pain when dramatic changes occur in peripheral nociceptors and central nociceptive pathways and the pain system is sensitised thereby leading to exaggerated responses to noxious stimuli (hyperalgesia) and responses to non-noxious stimuli (allo
-
Bufalin The use of FTAI can overcome the
2024-02-02

The use of FTAI can overcome the negative impact of low estrus detection efficiency, but implies effective synchrony of luteal function as well as synchronous growth and ovulation of a viable Bufalin follicle. Pregnancy rates obtained with FTAI may be comparable or better than those obtained after
-
In addition to differential expression of
2024-02-01

In addition to differential expression of AR protein primarily in surgical specimens, genetic alterations involving the AR gene have been documented in human CNQX cancer. Loss of heterozygosity at the AR locus was identified in all 3 informative cases of muscle-invasive bladder tumors, whereas, ins
-
The major phase trial NCT enrolled
2024-02-01

The major phase 2 trial (NCT01343966) enrolled 431 participants with mild to moderate AD who received either low-dose SC crenezumab 300 mg or placebo biweekly (n = 184) or high-dose intravenous crenezumab 15 mg/kg or placebo every 4 weeks (n = 247) for 68 weeks 38, 40. No significant treatment benef
-
We have recently begun to demonstrate this
2024-02-01

We have recently begun to demonstrate this concept by reporting a novel class of β-hairpin peptidomimetics, built on a piperidine-pyrrolidine semi-rigid β-turn inducer [12] and bearing two recognition pentapeptide sequences, designed on oligomeric and fibril structures of Aβ1-42 (compound 1, Fig. 1)
-
These findings suggest that eventually more than one lipoxyg
2024-02-01

These findings suggest that eventually more than one 12/15-lipoxygenase isoform may play a role in human atherosclerosis. Humans have two 12-lipoxygenases and two 15-lipoxygenases which show different expression patterns, substrate specificities and stereo-selective metabolism [1]. However, in RG738
-
Iberiotoxin receptor br Materials and methods br Results br
2024-02-01

Materials and methods Results Discussion Intracellular metabolic pathways of sugar, such as glycolysis and TCA cycle, provide material and energy for the synthesis of other substances, including amino acids. Thus, the content of sugars and their metabolic pathways are important for amino Ib
-
For the time being fluorescent in
2024-02-01

For the time being, fluorescent in situ hybridization (FISH) remains the ‘gold standard’ for ALK rearrangements diagnosis but immunohistochemistry has become a widely used pre-screening tool and the FDA recently approved the Ventana ALK (D5F3) CDx Assay (Ventana Medical Systems, Tucson, AZ) as a com
16179 records 209/1079 page Previous Next First page 上5页 206207208209210 下5页 Last page